Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease

Gut

Volumn 62, Issue 11, 2013, Pages 1625-1633

  Croci, Ilaria ^a   Byrne, Nuala M ^b   Choquette, Stéphane ^c   Hills, Andrew P ^d,e   Chachay, Veronique S ^a   Clouston, Andrew D ^a   O'Moore Sullivan, Trisha M ^d,f   Macdonald, Graeme A ^a,f   Prins, Johannes B ^a,d   Hickman, Ingrid J ^d,f  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; INSULIN;

ADULT; ARTICLE; BODY FAT; BODY MASS; CALORIMETRY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ENERGY EXPENDITURE; EXERCISE; FEMALE; FITNESS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID OXIDATION; LIVER HISTOLOGY; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESPIRATORY QUOTIENT;

CHRONIC LIVER DISEASE; FATTY LIVER; GLUCOSE METABOLISM; LIPID METABOLISM; LIPID OXIDATION;

ADULT; BASAL METABOLISM; CALORIMETRY, INDIRECT; CASE-CONTROL STUDIES; ENERGY METABOLISM; EXERCISE; EXERCISE TEST; FATTY LIVER; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; OXIDATION-REDUCTION; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 84885628762     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302789     Document Type: Article

References (59)

1. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
2. Daly AK, Ballestri S, Carulli L, et al. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2011;5:253-63.
3. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17.
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. (Pubitemid 36397405)
5. Korenblat KM, Fabbrini E, Mohammed BS, et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008;134:1369-75. (Pubitemid 351615354)
6. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
7. Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007;56:2759-65. (Pubitemid 350044919)
8. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29:478-85. (Pubitemid 37474259)
9. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-31. (Pubitemid 351173050)
10. Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc 2004;63:363-8. (Pubitemid 38787491)
11. Perseghin G, Bonfanti R, Magni S, et al. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab 2006;291:E697-703. (Pubitemid 44484910)
12. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. (Pubitemid 40591217)
13. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92. (Pubitemid 32246672)
14. Kotronen A, Seppala-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int 2009;29:1439-46.
15. Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-66.
16. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:1278-83.
17. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at www.idf.org (accessed 14 Feb 2007).
18. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8. (Pubitemid 40110657)
19. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 2002;12:49-51. (Pubitemid 34155261)
20. Pajunen P, Kotronen A, Korpi-Hyovalti E, et al. Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey. BMC Public Health 2011;11:754.
21. Booth FW, Lees SJ. Physically active subjects should be the control group. Med Sci Sports Exerc 2006;38:405-6. (Pubitemid 43364112)
22. Kleiner DE, Van Brunt EM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16. (Pubitemid 32240482)
24. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-20.
25. Despres JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-23.
26. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-23. (Pubitemid 9249478)
27. Gastaldelli A, Natali A, Vettor R, et al. Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig Liver Dis 2010;42: 310-19.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. Nosadini R, Avogaro A, Trevisan R, et al. Acetoacetate and 3-hydroxybutyrate kinetics in obese and insulin-dependent diabetic humans. Am J Physiol 1985;248: R611-20. (Pubitemid 15030663)
30. Hansen JE. Exercise instruments, schemes, and protocols for evaluating the dyspneic patient. Am Rev Respir Dis 1984;129:S25-7. (Pubitemid 14190976)
31. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983;55:628-34. (Pubitemid 13044099)
32. Achten J, Gleeson M, Jeukendrup AE. Determination of the exercise intensity that elicits maximal fat oxidation. Med Sci Sports Exerc 2002;34:92-7. (Pubitemid 34052381)
33. Jackson AS, Stanforth PR, Gagnon J, et al. The effect of sex, age and race on estimating percentage body fat from body mass index: The Heritage Family Study. Int J Obes Relat Metab Disord 2002;26:789-96. (Pubitemid 34620871)
34. Hodson L, Frayn KN. Hepatic fatty acid partitioning. Curr Opin Lipidol 2011;22:216-24.
35. Vianna CR, Huntgeburth M, Coppari R, et al. Hypomorphic mutation of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance. Cell Metab 2006;4:453-64. (Pubitemid 44817352)
36. Hashimoto T, Fujita T, Usuda N, et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 1999;274:19228-36.
37. Reid BN, Ables GP, Otlivanchik OA, et al. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 2008;283:13087-99.
38. Savage DB, Choi CS, Samuel VT, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116:817-24. (Pubitemid 43326891)
39. Vice E, Privette JD, Hickner RC, et al. Ketone body metabolism in lean and obese women. Metabolism 2005;54:1542-5. (Pubitemid 41527027)
40. Soeters MR, Sauerwein HP, Faas L, et al. Effects of insulin on ketogenesis following fasting in lean and obese men. Obesity (Silver Spring) 2009;17:1326-31.
41. Vega GL, Dunn FL, Grundy SM. Impaired hepatic ketogenesis in moderately obese men with hypertriglyceridemia. J Investig Med 2009;57:590-4.
42. Kelley DE, Goodpaster B, Wing RR, et al. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999;277:E1130-41. (Pubitemid 30046009)
43. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506. (Pubitemid 47187337)
44. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2011;55:1389-97.
45. Bell LN, Wang J, Muralidharan S, et al. Relationship between adipose tissue insulin resistance and liver histology in NASH: a PIVENS follow-up study. Hepatology. Published Online First: 24 April 2012. doi:101002/hep25805
46. Perez-Martin A, Dumortier M, Raynaud E, et al. Balance of substrate oxidation during submaximal exercise in lean and obese people. Diabetes Metab 2001;27:466-74. (Pubitemid 32852455)
47. Ghanassia E, Brun JF, Fedou C, et al. Substrate oxidation during exercise: type 2 diabetes is associated with a decrease in lipid oxidation and an earlier shift towards carbohydrate utilization. Diabetes Metab 2006;32:604-10. (Pubitemid 46145373)
48. Bruce CR, Kriketos AD, Cooney GJ, et al. Disassociation of muscle triglyceride content and insulin sensitivity after exercise training in patients with Type 2 diabetes. Diabetologia 2004;47:23-30. (Pubitemid 38141936)
49. Larsen S, Ara I, Rabol R, et al. Are substrate use during exercise and mitochondrial respiratory capacity decreased in arm and leg muscle in type 2 diabetes? Diabetologia 2009;52:1400-8.
50. Mogensen M, Vind BF, Hojlund K, et al. Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training. Diabetes Obes Metab 2009;11:874-83.
51. ACSM. American College of Sports Medicine's Guidelines of Exercise Testing and Prescription. Baltimore, Maryland: Lippincott Williams & Wilkins, 2006.
52. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009;301:2024-35.
53. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
54. Maiorana A, O'Driscoll G, Goodman C, et al. Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes. Diabetes Res Clin Pract 2002;56:115-23. (Pubitemid 34226627)
55. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003;52:2191-7. (Pubitemid 37059487)
56. Achten J, Jeukendrup AE. Optimizing fat oxidation through exercise and diet. Nutrition 2004;20:716-27. (Pubitemid 38798090)
57. Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011;93:1048-52.
58. Lee P, Day RO, Greenfield JR, et al. Formoterol, a highly beta(2)-selective agonist, increases energy expenditure and fat utilisation in men. Int J Obes (Lond). Published Online First: 30 May 2012. doi:101038/ijo201290.
59. Jeukendrup AE, Randell R. Fat burners: nutrition supplements that increase fat metabolism. Obes Rev 2011;12:841-51.